Swedish research-based biotechnology company Camurus AB (STO: CAMX) announced on Monday the launch 0f Oczyesa in Germany, marking its first introduction in the European Union following marketing authorisation from the European Commission.

Oczyesa, a once-monthly subcutaneous octreotide depot, is approved for maintenance treatment in adults with acromegaly who have responded to somatostatin analogues. The medicine, based on Camurus' FluidCrystal technology, does not require refrigeration and allows self-administration via an autoinjector pen. It is designed to provide sustained disease control and improve patient quality of life.

Clinical studies have shown that Oczyesa offers sustained biochemical control and symptom relief, with a safety profile consistent with first-generation long-acting somatostatin receptor ligands.

Acromegaly is a rare chronic condition affecting an estimated 70,000 people in the EU. It is typically caused by a pituitary tumour leading to excess growth hormone and elevated insulin growth factor-1 levels, resulting in abnormal bone and tissue growth.

Oczyesa is also being developed for gastroenteropancreatic neuroendocrine tumours and polycystic liver disease, and Camurus says it plans further launches of Oczyesa across additional EU countries.